SciELO - Scientific Electronic Library Online

 
vol.24 suppl.1Manejo de los casos en retratamiento de tuberculosis con sospecha de resistencia a fármacos índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Biomédica

versión impresa ISSN 0120-4157versión On-line ISSN 2590-7379

Resumen

GARCIA, Luis F  y  BARRERA, Luis F. Perspectivas para nuevas vacunas antituberculosas en la era posgenómica. Biomédica [online]. 2004, vol.24, suppl.1, pp.228-238. ISSN 0120-4157.

Perspectives for new anti-tuberculous vaccines in the post-genomic era Vaccination with attenuated Mycobacterium bovis BCG has been used as the routine procedure to immunize against tuberculosis. Since the efficacy of BCG vaccination is very controversial, the search for new immunoprophylatic tools against tuberculosis is an area of intense interest. Knowledge of the complete sequence of Mycobacterium tuberculosis (Mtb) H37Rv genome and the application of new immunological, biochemical and genetic technologies has led to a detailed understanding of the transcriptome and proteome of this bacterium. Approximately one-third of the human population is infected with Mtb; however, the bacillus is only detected once the symptoms appear and therefore most of the recent efforts have been devoted to the development of a post-infection vaccine. In theory, this vaccine (1) will give rise to an increase in the long-lasting specific immunity against Mtb, (2) will not have significant adverse effects, and (3) will be affordable for the people in third world countries. The main strategies that have been developed include the subunit vaccines, either as a mixture of relevant immunogenic proteins or DNA constructs, recombinant strains of Mycobacterium bovis BCG and Mtb, designed to secrete immunogenic proteins or with attenuated virulence, respectively, and DNA-based vaccines. The subunit vaccines are delivered either as mixtures of immunogenic proteins and adjuvants, or as naked DNA or by viral vectors in order to induce a potent Th1 response. Most of these vaccines have been tested in several kinds of animal models, but they do not fully reproduce the human pathology. However, the results obtained so far are very encouraging and have led to the development of phase I trials in humans.

Palabras clave : tuberculosis; vaccines; Mycobacterium tuberculosis.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons